NeurAxis Reports Double-Digit Growth and Approaches CPT Code Milestone for Neuromodulation Technology
ByAinvest
Tuesday, Nov 11, 2025 2:54 pm ET1min read
NRXS--
NeurAxis, Inc. (NRXS) has outlined commercial readiness for 2026, with double-digit growth continuing and a CPT code milestone nearing. The company is focused on executing its commercialization strategy for IB-Stim, a neuromodulation technology for pediatric and adult patients, and RED, a product for patients with evacuation disorders. Management highlighted progress in the quarter and emphasized the company's commitment to innovation and growth.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet